DECEMBER 2, 2024
Biophytis its participation in the 17th edition of the SCWD Congress (Society on Sarcopenia, Cachexia & Wasting Disorders), taking place from December 6 to 8,
SEPTEMBER 30, 2024
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities Biophytis publishes its financial results for the first half of 2024 and
JULY 22, 2024
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia Biophytis announces the deployment of its partnership strategy in Asia. To
July 11, 2024
Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity Biophytis announced that it has received Investigational New Drug
JULY 1st, 2024
Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis presented the roll-out and results of
JUNE 25, 2024
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted Biophytis announces the approval of all
JUNE 20, 2024
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million Biophytis announces the signature of an exclusive
JUNE 19, 2024
Biophytis extends its contract with Atlas to secure financing for its business activities Biophytis announces the extension of its bond financing agreement with Atlas, a
JUNE 12, 2024
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Seqens, an integrated global player in solutions and ingredients for
JUNE 10, 2024
Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Biophytis announces that it has submitted an